FDAsafety guidance66% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Pain Management · Combination Analgesic
- Sub-indication
- Pain
Related signal: FDA Approves Supplemental NDA for SYNALGOS-DC by Sun Pharma